Human Salivary duct autoantibody (SDA) ELISA Kit

Category: Assay Kits
Catalog
AE62528HU
(Ships in 5-10 business days)

Questions? Contact us

Call (800) 832-2611

arp-guarantee
- +
$0.00
More Information
Product Name Human Salivary duct autoantibody (SDA) ELISA Kit
Description B4GALNT2 catalyzes the last step in the biosynthesis of the human Sd(a) antigen through the addition of an N-acetylgalactosamine residue via a beta-1,4 linkage to a subterminal galactose residue substituted with an alpha-2,3-linked sialic acid. B4GALNT2 also catalyzes the last step in the biosynthesis of the Cad antigen. The longer transcript encodes a deduced 566-amino acid protein with a calculated molecular mass of 63.3 kD. It contains an N-terminal cytosolic domain, followed by a transmembrane domain and a long catalytic domain. The shorter transcript encodes a deduced 506-amino acid protein with calculated molecular mass of 57.0 kD. It has a different N-terminal cytosolic domain than the full-length form. Northern blot analysis detected B4GALNT2 transcripts of 8.8, 6.1, 4.7, 3.8, and 1.65 kb. This assay has high sensitivity and excellent specificity for detection of Human SDA. No significant cross-reactivity or interference between Human SDA and analogues was observed.
Method Competitive ELISA
Detection Range 0.312-20 ng/mL
Sensitivity 0.113 ng/mL
Reactivity Human
Sample Types Serum, Plasma, Other biological fluids.
Background B4GALNT2 catalyzes the last step in the biosynthesis of the human Sd(a) antigen through the addition of an N-acetylgalactosamine residue via a beta-1,4 linkage to a subterminal galactose residue substituted with an alpha-2,3-linked sialic acid. B4GALNT2 also catalyzes the last step in the biosynthesis of the Cad antigen. The longer transcript encodes a deduced 566-amino acid protein with a calculated molecular mass of 63.3 kD. It contains an N-terminal cytosolic domain, followed by a transmembrane domain and a long catalytic domain. The shorter transcript encodes a deduced 506-amino acid protein with calculated molecular mass of 57.0 kD. It has a different N-terminal cytosolic domain than the full-length form. Northern blot analysis detected B4GALNT2 transcripts of 8.8, 6.1, 4.7, 3.8, and 1.65 kb.
Supplier Abebio

All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.